“…All of these transcripts share a common 118 amino acid AT2-receptor interacting domain (ID), which suggests that all 5 MTUS1 transcripts interact with the AT2-receptor and induce atypical signal transduction pathways including at least three intracellular cascades involving protein phosphatase activation, nitric oxide regulation, and phospholipase A2 stimulation (Knowle et al, 2000). Additionally, recent studies have shown that MTUS1 loss or downregulation is associated with enhanced tumor proliferation, poor tumor differentiation, and poor prognosis in bladder cancer (Xiao et al, 2012), gastric cancer (Li et al, 2014a), salivary adenoid cystic carcinoma (Zhao et al, 2015), and other cancers (Louis et al, 2010; Louis et al, 2011; Ding et al, 2012; Varghayee et al, 2015). In addition, MTUS1 has been shown to interfere with activation of the ERK2 pathway and to inhibit proliferation of cells stimulated with growth factors, such as insulin, bFGF, PDGF, and EGF (Nouet et al, 2004; Zuern et al, 2010).…”